Humana Prices $1 Billion Junior Subordinated Notes Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HUM?
Source: seekingalpha
- Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
- Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
- Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 183.110
Low
231.00
Averages
290.39
High
344.00
Current: 183.110
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Prices $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
- Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
- Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
See More
HUM Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $180.00 put option is $10.10, and if an investor sells this contract, they commit to buying the stock at $180.00, effectively lowering their cost basis to $169.90, which is approximately a 1% discount from the current price of $181.36, making it an attractive alternative for potential buyers.
- Yield Potential Analysis: Should the put option expire worthless, it would yield a 5.61% return on the cash commitment, equating to an annualized yield of 41.00%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $185.00 call option has a current bid of $9.80, and if an investor buys HUM shares at $181.36 and sells this call, they could achieve a total return of 7.41% if the stock is called away at expiration, indicating a lucrative strategy.
- Risk-Reward Balance: Given that the $185.00 strike price represents a 2% premium over the current stock price, the current data suggests a 50% chance of the call option expiring worthless, allowing investors to retain both their shares and the premium collected, thereby enhancing investment security.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
DAV Renews Partnership with Humana to Support Veterans
- Ongoing Partnership: DAV (Disabled American Veterans) has renewed its partnership with Humana, highlighting a long-term commitment to supporting veterans and their families while enhancing Humana's investment in veteran service organizations.
- Service Expansion: Humana is dedicated to addressing various challenges affecting veteran well-being, such as hunger, homelessness, and financial strain, by collaborating with communities, veteran service organizations, and healthcare providers to improve overall health outcomes for veterans.
- Increased Resources: Over the past six years, Humana has consistently invested in DAV's mission, assisting over 1 million veterans and their families in accessing healthcare, disability compensation, and employment resources, ensuring they receive the benefits they have earned.
- Shared Vision: Leaders from both DAV and Humana expressed that their collaboration not only enhances the resources and quality of care for veterans but also demonstrates a strong commitment to the veteran community, with plans to continue working together to achieve positive outcomes in the future.
See More
DAV Renews Partnership with Humana to Support Veterans
- Ongoing Partnership: DAV (Disabled American Veterans) has renewed its partnership with Humana, highlighting a long-term commitment to supporting veterans and their families, which is expected to enhance veterans' health and well-being.
- Investment Expansion: Humana's investment in veteran service organizations will help address challenges such as hunger, homelessness, and financial strain, thereby improving the quality of life for veterans and reinforcing corporate social responsibility.
- Service Coverage: Each year, DAV assists over 1 million veterans and their families in accessing healthcare, disability compensation, and employment resources, ensuring a smooth transition to civilian life and demonstrating steadfast support for veterans' rights.
- Leadership Commitment: Humana executives stated that continuing the collaboration with DAV aims to expand resources and services, reflecting a deep commitment to the veteran community, which is expected to drive more collaborative outcomes in the future.
See More
Humana Partners to Enhance Heart Health for Medicare Advantage Members
- Partnership Expansion: Humana has announced new partnerships with CVAUSA's Novocardia Care Solutions, Karoo Health, US Heart and Vascular, and Chamber Cardio to enhance its cardiac care program, aiming to improve heart health for eligible Medicare Advantage members through value-based care.
- Enhanced Services: The new agreements provide Humana's Medicare Advantage members with 24/7 hotline access, remote monitoring tools, and integrated team support, enabling better management of heart conditions and reducing hospitalization rates, thereby improving quality of life and health outcomes.
- Value-Based Care Impact: Humana's analysis indicates that value-based care leads to higher quality care and better adherence to evidence-based medicine for cardiac patients, underscoring the company's commitment to delivering high-quality, whole-person care.
- Service Availability: Humana's cardiac care services are now available across multiple states, including Florida, Georgia, South Carolina, Illinois, North Carolina, Iowa, Arizona, Alabama, Mississippi, Louisiana, Maryland, and Texas, ensuring that more members can benefit from these enhanced services.
See More
Humana Prices $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
- Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
- Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
See More
HUM Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $180.00 put option is $10.10, and if an investor sells this contract, they commit to buying the stock at $180.00, effectively lowering their cost basis to $169.90, which is approximately a 1% discount from the current price of $181.36, making it an attractive alternative for potential buyers.
- Yield Potential Analysis: Should the put option expire worthless, it would yield a 5.61% return on the cash commitment, equating to an annualized yield of 41.00%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $185.00 call option has a current bid of $9.80, and if an investor buys HUM shares at $181.36 and sells this call, they could achieve a total return of 7.41% if the stock is called away at expiration, indicating a lucrative strategy.
- Risk-Reward Balance: Given that the $185.00 strike price represents a 2% premium over the current stock price, the current data suggests a 50% chance of the call option expiring worthless, allowing investors to retain both their shares and the premium collected, thereby enhancing investment security.
See More
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
- Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
- Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
- Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
- Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
See More
DAV Renews Partnership with Humana to Support Veterans
- Ongoing Partnership: DAV (Disabled American Veterans) has renewed its partnership with Humana, highlighting a long-term commitment to supporting veterans and their families while enhancing Humana's investment in veteran service organizations.
- Service Expansion: Humana is dedicated to addressing various challenges affecting veteran well-being, such as hunger, homelessness, and financial strain, by collaborating with communities, veteran service organizations, and healthcare providers to improve overall health outcomes for veterans.
- Increased Resources: Over the past six years, Humana has consistently invested in DAV's mission, assisting over 1 million veterans and their families in accessing healthcare, disability compensation, and employment resources, ensuring they receive the benefits they have earned.
- Shared Vision: Leaders from both DAV and Humana expressed that their collaboration not only enhances the resources and quality of care for veterans but also demonstrates a strong commitment to the veteran community, with plans to continue working together to achieve positive outcomes in the future.
See More
DAV Renews Partnership with Humana to Support Veterans
- Ongoing Partnership: DAV (Disabled American Veterans) has renewed its partnership with Humana, highlighting a long-term commitment to supporting veterans and their families, which is expected to enhance veterans' health and well-being.
- Investment Expansion: Humana's investment in veteran service organizations will help address challenges such as hunger, homelessness, and financial strain, thereby improving the quality of life for veterans and reinforcing corporate social responsibility.
- Service Coverage: Each year, DAV assists over 1 million veterans and their families in accessing healthcare, disability compensation, and employment resources, ensuring a smooth transition to civilian life and demonstrating steadfast support for veterans' rights.
- Leadership Commitment: Humana executives stated that continuing the collaboration with DAV aims to expand resources and services, reflecting a deep commitment to the veteran community, which is expected to drive more collaborative outcomes in the future.
See More
Humana Partners to Enhance Heart Health for Medicare Advantage Members
- Partnership Expansion: Humana has announced new partnerships with CVAUSA's Novocardia Care Solutions, Karoo Health, US Heart and Vascular, and Chamber Cardio to enhance its cardiac care program, aiming to improve heart health for eligible Medicare Advantage members through value-based care.
- Enhanced Services: The new agreements provide Humana's Medicare Advantage members with 24/7 hotline access, remote monitoring tools, and integrated team support, enabling better management of heart conditions and reducing hospitalization rates, thereby improving quality of life and health outcomes.
- Value-Based Care Impact: Humana's analysis indicates that value-based care leads to higher quality care and better adherence to evidence-based medicine for cardiac patients, underscoring the company's commitment to delivering high-quality, whole-person care.
- Service Availability: Humana's cardiac care services are now available across multiple states, including Florida, Georgia, South Carolina, Illinois, North Carolina, Iowa, Arizona, Alabama, Mississippi, Louisiana, Maryland, and Texas, ensuring that more members can benefit from these enhanced services.
See More
